CIPN

Chemotherapy‑induced peripheral neuropathy (CIPN) affects more than half of patients treated with neurotoxic agents such as platinum drugs, taxanes, and vinca alkaloids. It causes pain, numbness, and functional impairment that can force oncologists to reduce or discontinue life‑saving therapy. Today, there are no FDA-approved, mechanism targeted treatments for CIPN - leaving a major unmet medical and commercial need.

• High prevalence among patients receiving standard chemotherapies.

• Significant impact on dose intensity, treatment outcomes, morbidity and mortality.

• No FDA‑approved drugs specifically indicated for prevention or treatment of CIPN.

• Substantial cost burden and quality‑of‑life impact for patients and health systems.